- Home
- IGMS vs MASS Comparison
IGMS vs MASS Comparison
Compare IGMS & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- MASS
- Stock Information
- Founded
- IGMS 1993
- MASS 2012
- Country
- IGMS United States
- MASS United States
- Employees
- IGMS N/A
- MASS N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- MASS Medical/Dental Instruments
- Sector
- IGMS Health Care
- MASS Health Care
- Exchange
- IGMS Nasdaq
- MASS Nasdaq
- Market Cap
- IGMS 82.1M
- MASS 84.3M
- IPO Year
- IGMS 2019
- MASS 2020
- Fundamental
- Price
- IGMS $1.26
- MASS $5.95
- Analyst Decision
- IGMS Hold
- MASS Buy
- Analyst Count
- IGMS 8
- MASS 3
- Target Price
- IGMS $6.14
- MASS $5.33
- AVG Volume (30 Days)
- IGMS 172.4K
- MASS 569.5K
- Earning Date
- IGMS 05-13-2025
- MASS 05-13-2025
- Dividend Yield
- IGMS N/A
- MASS N/A
- EPS Growth
- IGMS N/A
- MASS N/A
- EPS
- IGMS N/A
- MASS N/A
- Revenue
- IGMS $2,681,000.00
- MASS $63,986,000.00
- Revenue This Year
- IGMS $124.45
- MASS N/A
- Revenue Next Year
- IGMS $45.07
- MASS $19.22
- P/E Ratio
- IGMS N/A
- MASS N/A
- Revenue Growth
- IGMS 27.36
- MASS 32.85
- 52 Week Low
- IGMS $0.92
- MASS $1.81
- 52 Week High
- IGMS $22.50
- MASS $6.44
- Technical
- Relative Strength Index (RSI)
- IGMS 51.89
- MASS 62.38
- Support Level
- IGMS $1.13
- MASS $4.47
- Resistance Level
- IGMS $1.42
- MASS $6.27
- Average True Range (ATR)
- IGMS 0.09
- MASS 0.51
- MACD
- IGMS 0.01
- MASS 0.08
- Stochastic Oscillator
- IGMS 52.94
- MASS 84.54
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.